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Abstract
Background: Chronic depression is characterized by a high degree of early life trauma, psychosocial impairment,
and deficits in social cognition. Undisturbed recognition and processing of facial emotions are basic prerequisites
for smooth social interactions. Intranasal application of the neuropeptide oxytocin has been reported to enhance
emotion recognition in neuropsychiatric disorders and healthy individuals. We therefore investigated whether
oxytocin modulates attention to emotional faces in patients with chronic depression.
Methods: In this double-blind, randomized, controlled study, 43 patients received a single dose of oxytocin or
placebo nasal spray and were tested while fulfilling a facial dot probe task. We assessed reaction times to neutral
probes presented at the location of one of two faces depicting happy, angry, or neutral expressions as a prime.
Results: When comparing reaction times to the congruent (prime and probe at the same location) with incongruent
presentation of facial emotions, neither the placebo nor oxytocin group showed an attentional preference for emotional
facial expressions in terms of a threat bias. However, oxytocin treatment did reveal two specific effects: it generally
reduced the allocation of attention towards angry facial expressions, and it increased sustained attention towards happy
faces, specifically under conditions of heightened awareness, i.e. trials with longer primes.
Conclusions: We investigated a heterogeneous group of medicated male and female patients. We conclude that
oxytocin does modulate basic factors of facial emotion processing in chronic depression. Our findings encourage further
investigations assessing the therapeutic potential of oxytocin in chronic depression.
Trial registration: EUDRA-CT 2010-020956-69. Date registered: 23 February 2011.
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Background
In about a third of patients with major depressive disorder,
the depression becomes chronic, defined as the illness
lasting longer than two years [1, 2]. However, chronic
depression is not just the prolonged course of a major de-
pressive disorder - it differs in several key psychopatho-
logical aspects from the episodic course of depression.
Chronically depressed patients are characterized by a high
degree of early life trauma, specifically emotional abuse
and neglect [3]; they report more negative interpersonal
experiences with significant others than patients with epi-
sodic depression [4] and experience worse impaired psy-
chosocial function [1]. These features, and clinical
experience from the psychological treatment of chronic-
ally depressed patients, have led to the hypothesis that
patients with chronic depression are arrested in the “pre-
operational developmental stage” according to Piaget,
which is characterized by an egocentric perspective on the
world and impaired interpersonal empathy and theory of
mind [5–7].
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Facial emotion recognition and attentional bias in
depression
Facial emotion recognition contributes to the cognitive
facet of empathy and represents a basic requisite to under-
standing social interactions. Numerous studies have
assessed facial emotion recognition in major depression
(for a review: [8]). Although the accuracy of facial emotion
recognition seems to be normal, there is considerable evi-
dence of a negative response bias towards sadness and
increased vigilance and selective attention to negative
emotions in depressed individuals [9]. Facial emotion rec-
ognition and attentional bias towards negative facial cues
have not been assessed specifically in chronic depression.
Given the high degree of psychosocial impairment that
chronically depressed patients suffer, better understanding
of the attentional processes for social signals in chronic
depression and their neurobiological modulation might be
especially relevant for clinical treatment.
The role of attention in face processing
Socially-relevant stimuli such as emotional facial expres-
sions normally capture our attention. Enhanced attention
to emotional faces can be inferred from studies showing
that emotional faces are more easily detected than neutral
stimuli, as evident in visual search paradigms [10] and
rapid serial presentation paradigms [11]. Thus, increased
attentional preference for a given stimulus category indi-
cates the greater motivational relevance or saliency of this
specific stimulus.
A widely-used paradigm to assess attentional preference
for a given category of emotional stimuli is the dot probe
task [12]. In short, in the classical dot probe task, two
stimuli (e.g. an emotional and neutral face) are presented
simultaneously on a screen, followed by a probe, which is
presented either at the target’s location (congruent) or at
the distractor’s location (incongruent). Attentional prefer-
ence for the target is inferred from the so-called congru-
ency effect, i.e. if the reaction times (RTs) are significantly
faster in congruent than incongruent trials.
Although several studies have confirmed a robust,
threat-related bias in terms of an enhanced congruency
effect in response to highly aversive/threatening stimuli
in anxious populations, the congruency effect has been
revealed as less consistent in healthy or subclinical sam-
ples [13]. It should be noted that most studies used ver-
bal material or complex, emotionally-laden visual scenes
as target stimuli in the dot probe task.
There is considerable evidence that depressed patients
demonstrate an attentional bias towards negative informa-
tion including social cues such as negative facial exp-
ressions (for a review: [9]). Initial evidence of biased
attention towards emotional facial expressions arises from
studies involving subclinical dysphoric samples. Dysphoric
people demonstrate the tendency to avoid happy facial
expressions [14], and low dysphoria is associated with an
attentional bias away from angry faces [15]. There is a
paucity of studies investigating patients diagnosed with
major depression. Initial evidence exists of an attentional
bias towards sad faces [16, 17], and angry faces [18], al-
though other investigators did not detect biased attention
to either facial stimuli in depression [19].
Some researchers have argued in favor of at least two
processes underlying the congruency effect: the effect of
initial allocation of attention to the salient prime in con-
gruent trials, and the inability to reallocate attention to
the probe’s location in incongruent trials. While the
former might be largely due to vigilance, the latter can
be referred to as adherence, or the difficulty of disen-
gaging from the prime. Indeed, previous studies found
that the congruency effect in the dot-probe task was
largely due to enhanced adherence to the threat stimulus
rather than increased vigilance [20, 21]. It might there-
fore be particularly interesting to explicitly differentiate
between treatment effects on the initial allocation of at-
tention towards a specific stimulus category and atten-
tional adherence to the stimulus.
Oxytocin, face processing, and social attention
The nine-amino-acid oxytocin is known to modulate so-
cial interaction in animals and humans [22, 23]. Experi-
mental studies in humans have associated oxytocin with
an enhanced ability to recognize facial emotions [24] in
both healthy individuals [25–28] and in those with im-
paired facial emotion recognition abilities such as autism
[29, 30] or schizophrenia [31, 32]. There is recent evi-
dence that oxytocin increases covert attention to positive
facial cues in healthy males [33]. Another study using a
spatial cueing paradigm reported facilitated attentional
disengagement from negative facial expression stimuli
after the intranasal administration of oxytocin [34]. More-
over, there is evidence of positive effects on overt visual at-
tention to the eye region in both neutral and emotional
faces [35–37], suggesting that attention modulation might
be a significant mediator in the beneficial effects of oxyto-
cin on emotion recognition, although this link must still
be demonstrated [27]. Finally, there are initial findings that
oxytocin also has beneficial effects on affective symptoms
and social cognitive functioning in patients with episodic
depression [38, 39].
Aims and hypotheses
The present study aimed to investigate whether a single
dose of intranasally applied oxytocin would modulate at-
tention towards social signals of threat (angry faces) and
social approach (happy faces) in a group of patients with
chronic depression. Angry faces were chosen on the
basis of previous studies addressing the attention effects
of oxytocin in a social context [33–35] and previous
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findings demonstrating a bias towards angry faces in de-
pressed patients [18, 40]. Ellenbogen et al. demonstrated
that oxytocin attenuated the attentional bias to masked
angry faces in persons with high depression scores [34].
Based on findings of reduced attention to positive facial
cues in depression and oxytocin’s effects on attention
summarized above, we specifically hypothesized that pa-
tients receiving oxytocin prior to a facial dot probe task
would reveal greater attention towards happy faces than
placebo controls, as indicated by a greater congruency
effect. Furthermore, we were interested in determining
whether oxytocin treatment would affect initial attention
allocation or adherence to the emotional target.
Methods
Participants
Forty-three patients with chronic depression were re-
cruited from the in-patient and out-patient units of the
Department of Psychiatry and Psychotherapy at the
University Medical Center Freiburg. Patients were con-
sidered for the study if they met the criteria for chronic
depression as defined by depressive symptomatology for
more than two years in the course of a depressive epi-
sode or a recurrent depressive disorder (ICD-10: F32.1,
F32.2, F33.1, F33.2). In addition, many patients fulfilled
the criteria for dysthymia (ICD-10: F34.0) and therefore
suffered from double depression (depressive episode +
dysthymia). Patients were excluded from the study if
they met any of the following criteria: bipolar disorder,
current psychotic symptoms, alcohol or drug addiction,
a clinical autism diagnosis, severe uncorrected visual
impairment. Of the total sample, 41 were taking psy-
choactive medication: 9 patients were taking SSRI, 15
SSNRI, 7 tri-/tetracyclic antidepressants, 6 DNRI, and 4
were taking a neuroleptic or others. Patients were ran-
domly allocated to receive a single dose of intranasally
administered oxytocin (n = 22) or a placebo (n = 21) be-
fore the dot-probe task under double-blind conditions.
For demographic and clinical characteristics of these
groups, see Table 1. The study protocol was approved by
the ethics committee of the University of Freiburg.
Patients provided written-informed consent once the
study procedures had been fully explained.
Psychometric assessment
All patients completed the Beck Depression Inventory [41],
the State-Trait-Anxiety Questionnaire [42] and multi-
dimensional mood questionnaire [43] to assess trait depres-
sion, anxiety and changes in calmness, wakefulness and
mood over the course of the experiment. The short version
of the multidimensional mood questionnaire employed here
comprises 12 items on three scales, measuring state calm-
ness, wakefulness, and mood using 5-point Likert scales.
The questionnaire has proven good reliability and validity
and is a sensitive measure to capture state-dependent
changes in calmness, wakefulness and mood [43].
Experimental procedures
After completing demographic, clinical and mood-state
questionnaires, patients self-administered 6 puffs of Synto-
cinon® nasal spray (Novartis, Basel, Switzerland; 3 puffs per
nostril, containing 4 IU oxytocin each) or a placebo under
the supervision of the experimenter. After approx. 45 min,
participants completed a basic facial emotion recognition
experiment before being asked to complete a dot-probe
task to assess attentional preference for facial stimuli with
varying valence [12]. The dot-probe thus started approx.
60 min after intranasal oxytocin administration.
As prime stimuli, happy, angry and neutral facial expres-
sions of 40 persons (20 male/20 female) were selected
from the Karolinska Directed Emotional Faces database
[44]. An overview of trial structure and experimental con-
ditions is provided in Fig. 1. A trial started with a blank
screen for 1000 ms followed by a fixation cross for 750 to
1500 ms. Then a pair of angry/neutral, happy/neutral or
neutral/neutral faces of the same person was presented
(each 295 × 400 pixels, 12.2 × 16.5° visual angle) with an
vertical offset of +/− 200 pixels (8.3° visual angle) from the
screen center lasting 100, 600, or 1200 ms. Immediately
following the presentation of faces, a dot probe was pre-
sented at the location of one of the faces. For the angry/
neutral and happy/neutral pairs, the probe (a small black
box, 10 × 10 pixels) appeared in the center of the emo-
tional face (congruent) or the neutral face (incongruent)
in half of the trials. Participants were asked to press as
Table 1 Demographic and clinical characteristics of the study
groups
Placebo (n = 21) Oxytocin (n = 22)
m (s.d.) m (s.d.)
Age 47.2 (9.0) 46.7 (11.1)
Sex (m/f) 9/12 9/13
Years in school 11.3 (2.0) 11.0 (1.5)
IQ (WST) 106.6 (9.7) 108.7 (9.6)
Depression (BDI) 28.0 (9.5) 29.1 (11.9)
Trait anxiety (STAI) 60.9 (8.3) 61.4 (8.1)
Medication (y/n) 19/2 22/0
Illness duration (years) 12.9 (10.2) 14.8 (12.1)
Calmness pre 13.0 (3.2) 12.5 (2.5)
post 11.8 (2.9) 11.6 (2.4)
Wakefulness pre 13.1 (3.5) 12.8 (4.2)
post 10.3 (3.6) 11.0 (3.4)
Mood pre 12.9 (3.2) 12.5 (2.5)
post 11.8 (2.9) 11.6 (2.4)
WST, Wortschatztest; BDI, Beck Depression Inventory; STAI, State-Trait
Anxiety Inventory
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quickly as possible either of two buttons located in front
of them on a table to indicate the probe’s location. The
numbers of correct responses and RTs to the dot probes
were recorded. At each presentation time (100, 600,
1200 ms), 120 trials were presented comprising 40 trials
for each pairing of faces (angry-neutral, happy-neutral,
neutral-neutral). In all, there were 360 trials lasting a
maximum approx. 30 min. The experiment was run on a
Windows PC with a 22” TFT display (40.8 × 30.6 cm;
1650 × 1050 pixel) using Presentation (Version 12.1, Neu-
robehavioral Systems, Albany CA, USA). Viewing distance
was kept constant at 65 cm using a chin-/headrest.
Statistical analyses
Raw RTs in erroneous trials with erroneous responses,
and RTs below 300 ms and above 1500 ms were excluded
from further analysis. In all, 15,480 trials were presented
to the 43 participants in the study. Of these, 480 (3.1 %)
were discarded from the analysis, 145 (0.9 %) were out of
the time range and 335 (2.2 %) were errors. RT outliers
and errors did not differ between the experimental condi-
tions (all p < .10).
Raw RTs were analyzed via a four-way ANOVA com-
prising the factors group (oxytocin, placebo), prime dur-
ation (100, 600, 1000 ms), prime valence (happy, angry),
and condition (congruent, incongruent).
Attentional bias for specific emotional facial expressions
was calculated by subtracting averaged RTs to congruent
trials from averaged RTs to incongruent trials within each
condition (congruency effect). These bias scores were sub-
ject to a three-way ANOVA with group (oxytocin, placebo)
as the between-subject factor, and presentation duration
(100, 600, 1200 ms) and prime valence (angry, happy) as
within-subject factors.
We also calculated prime-valence effects on initial al-
location and adherence by contrasting RTs on congruent
and incongruent trials with RTs on neutral control trials.
Faster RT to congruent than to neutral trials reveals ini-
tial allocation of attention to the position of the salient
prime location and result in positive values for the
contrast ΔRTallocation = RTneutral – RTcongruent. In turn,
responding slower to incongruent than to neutral trials
indicates adherence to the position of the salient prime
and result in positive values for the contrast ΔRTadherence =
RTincongruent – RTneutral. Again, both allocation and adher-
ence scores were subjected to separate three-way ANOVAs
with the factors group, presentation duration, and prime
valence. Post-hoc testing employed separate follow-up
two-way ANOVAs for happy and angry primes with the
factors group (oxytocin, placebo) and prime duration (100,
600, 1200 ms).
Statistical significance was set to p < .05. In case of
non-homogenous variances, the Greenhouse-Geisser
correction was employed. All statistical analyses were
done with SPSS 20 for Windows.
Results
Demographic and clinical characteristics of the study
group
The two study groups were equivalent regarding age,
education, gender distribution, IQ, trait anxiety, and de-
pression. Although we noted a significant reduction in
calmness, wakefulness, and mood over the course of the
experiment (all p < .05), this effect did not substantially
differ between the oxytocin and placebo group (all
p > .10). Descriptive data are given in Table 1.
Raw reaction time data
In the first step, we analyzed differences in raw RT data for
the factors drug condition, congruency, prime duration,
and emotional valence of prime. The four-way ANOVA re-
vealed a significant main effect of prime duration, indicat-
ing overall shorter RTs on primes with longer duration
(F[2,82] = 16.83; p < .001; η2part = .291). No other effect
attained significance, indicating that RTs were neither
modulated by the emotional valence of the prime nor by
the probe’s location. Furthermore, we observed no drug-
condition effect (Table 2).
Attentional bias – congruency effect
To analyze the modulation of attentional preference for
happy vs. angry faces at different prime durations, we
analyzed attentional bias scores (difference between RTs
to congruent vs. incongruent trials). In the three-way
ANOVA testing for effects of prime duration, prime
valence and drug condition, neither any of the main ef-
fects nor any of the interactions attained significance.
We thus detected no overall modulation of attentional
Fig. 1 Trial structure and experimental conditions of the dot probe
task. Following a fixation cross for 750–1500 ms, primes were
presented simultaneously for either 100, 600, or 1200 ms. RTs were
measured from the onset of the dot probe which followed the
primes until the button press
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preference for emotional facial expressions in terms of a
congruency effect (Table 3).
Allocation vs. adherence
To further investigate effects on the initial allocation of at-
tention towards the salient emotional prime and effects
on adherence on salient primes, we performed two separ-
ate three-way ANOVAs. In the allocation scores, we noted
significant interaction between prime duration and drug
condition (F[2,82] = 3.54; p = .033; η2part = .080): For both
happy and angry faces, the placebo group displayed a
greater initial allocation of attention with increasing dur-
ation of the salient emotional prime, while the oxytocin
group demonstrated decreased initial allocation to-
wards the emotional prime with increasing prime dur-
ation (Fig. 2a). In the follow-up two-way ANOVA with
the factors group and prime duration for angry primes,
we noted a significant group by prime duration inter-
action (F[2,82] = 3.20; p = .046, η2part = .073), while there
was no such effect in the follow-up ANOVA for happy
faces (F[2,82] = 1.87; p = .161), suggesting reduced alloca-
tion of attention with increasing duration of the angry
prime after oxytocin treatment.
For adherence scores, i.e. slower attentional disengage-
ment from the salient prime, we identified a significant
interaction between prime valence and drug condition
(F[2,82] = 6.64; p = .014; η2part = .139) and a marginally
significant interaction of prime valence, prime duration
and drug condition (F[2,82] = 2.57; p = .083; η2part = .059).
While the oxytocin group demonstrated greater adherence
to happy faces with increasing prime duration than the
placebo group, there was no such modulation for angry
faces (Fig. 2b). Follow-up two-way ANOVAs with the fac-
tors group and prime duration confirmed the differential
effect of oxytocin with happy and angry faces: for happy
faces a significant prime duration by drug interaction was
observed, (F[2,82] = 3.21; p = .046; η2part = .073), while
there was no significant effect in association with the
angry faces (F[2,82] = 0.08; p = .992).
Discussion
This study provides initial evidence for an oxytocin-
induced modulation of attention towards positive and
negative social signals in chronic depression. Although
no congruency effect was observed in the present study,
and the placebo group demonstrated no negativity or
threat-bias, oxytocin did reduce the initial allocation of
attention towards angry faces, and it increased sustained
attention towards happy faces, specifically under condi-
tions of heightened awareness, i.e. during trials with lon-
ger prime duration.
The lack of an overall attentional threat bias concurs
with some previous studies and might be attributable to
this measure’s limited sensitivity, especially when attention
allocation and adherence reveal reversed effects and thus
cancel each other out [21]. Inspecting the pattern of
results (Fig. 2), this might be the case in the present study,
since oxytocin exhibits opposing effects in conjunction
with allocation and adherence of attention depending on
the emotion presented.
Increased adherence or an attenuated tendency to dis-
engage from the incongruent salient prime seems to be
the primary factor underlying the congruency effect in in-
vestigations with anxious patients [20, 21]. Although there
are very few studies addressing visual attention to specific
social cues in depression and (to our knowledge) none
examining chronic depression, there is initial evidence
that patients suffering from major depression display
reduced attention to positive social cues (happy faces) and
increased attention to negative (sad and angry) ones
[17, 18, 45]. In this study, we report increased adherence
to positive social cues after oxytocin treatment, a finding
in line with an earlier study using eye-tracking in healthy
Table 2 Average raw RTs in milliseconds (s.d.) for the
experimental conditions in the dot-probe task
Placebo (n = 21) Oxytocin (n = 22)
Congruent Incongruent Congruent Incongruent
Happy
100 ms 608 (96) 600 (94) 612 (99) 590 (83)
600 ms 578 (95) 575 (95) 579 (93) 572 (95)
1200 ms 551 (93) 554 (81) 577 (95) 578 (90)
Angry
100 ms 598 (117) 585 (107) 602 (82) 609 (100)
600 ms 568 (89) 562 (102) 580 (83) 579 (85)
1200 ms 550 (93) 555 (92) 581 (97) 568 (91)
Neutral
100 ms 586 (92) 599 (86)
600 ms 565 (85) 570 (80)
1200 ms 555 (85) 559 (83)
Table 3 Attentional bias scores (in ms) for the different
experimental conditions in the dot-probe task
Placebo (n = 21) Oxytocin (n = 22)
m (s.d.) m (s.d.)
Happy
100 ms −7.7 (38.8) −21.4 (55.5)
600 ms −2.7 (46.8) −7.9 (43.8)
1200 ms 3.0 (47.4) 0.9 (35.5)
Angry
100 ms −13.3 (44.3) 8.3 (39.7)
600 ms −6.2 (41.9) −0.6 (38.6)
1200 ms 4.0 (40.7) −11.6 (52.7)
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participants [35]. This effect might in part compensate for
the attentional negativity bias previously observed, and
might thus demonstrate beneficial effects on social inter-
action in chronic depression.
Furthermore, our data suggest decreased initial alloca-
tion for negative facial expressions in the group receiv-
ing oxytocin compared to placebo. Notably, a recent
study demonstrated that selective attention toward angry
faces is a significant predictor for the recurrence of
depression [40]. In light of these results, an oxytocin-
induced shift of attention from negative to positive social
cues might exert protective effects in the course of
chronic illness or recurrent depression. However, the
oxytocin group’s negative allocation-score values regard-
ing increased prime durations indicate prolonged reac-
tion times to congruent probes, although the attentional
focus is presumably primed to the correct location. One
plausible explanation for this paradoxical priming effect is
the possibility that processing the facial stimulus interferes
with the response to the probe. Negative allocation scores
might therefore also indicate increased adherence to the
salient congruent prime, and could reveal increased atten-
tion to the prime faces rather than a reduced allocation of
attention.
The following limitations should be acknowledged.
Although we observed significant modulations in atten-
tional processes via the experimental intranasal adminis-
tration of a single dose of oxytocin in a group of patients
with chronic depression, interpretations regarding its
clinical application should be made cautiously. First,
the overall effects observed in this study were small and
thus require replication. Attention to social stimuli is
Fig. 2 Effects of oxytocin on the initial allocation of attention to the emotional prime and adherence on the emotional prime face as a function
of presentation duration and emotional valence. a Allocation scores are calculated by subtracting the average RT to congruent trials from the
average RT to neutral trials. Thus, negative values represent longer RTs to probes at the congruent location of the emotional face compared to
neutral trials. b Adherence scores are calculated by subtracting the average RT to neutral trials from the average RT to incongruent trials. Thus,
positive scores indicate sustained attention to the emotional prime
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obviously just one of many other factors contributing to
real-life social interactions. Follow-up studies are thus
needed to evaluate the relative contribution of attentional
processes to social functioning. Second, we investigated a
heterogeneous group of male and female patients of
whom almost all were taking psychoactive medication. It
would therefore be an interesting topic for future studies
to elucidate the role of sex and gonadal steroids in the
effects we observed, as well as any interactions with sero-
tonergic or noradrenergic medication. Third, long-term
randomized controlled clinical trials are needed to evalu-
ate the usefulness of intranasal oxytocin as an add-on to
well-established cognitive behavioral treatment programs
or pharmacotherapy in chronic depression. Previous stud-
ies suggest altered facial emotion perception related to
personality disorders [46, 47]. In the present study none of
the patients had a clinical diagnosis of BPD or any other
personality disorder. However, lacking a structured inter-
view, we cannot rule out that some patients met some of
those criteria.
Conclusions
To summarize: there is increasing evidence of a role played
by oxytocin in human social cognition and interaction
[22, 23]. In addition, recent studies suggest that individuals
with impaired social cognitive abilities might benefit
from increased availability of central nervous oxytocin
[29, 31, 48–52]. Previous studies with depressed patients
have reported positive effects of oxytocin on affective symp-
toms and social cognition [38, 39]. Here we report in-
creased attention to emotional faces in chronic depression
using an experimental paradigm specifically tailored to dis-
entangle the effects on allocation and adherence of visual
attention for positive and negative social cues. In particular,
our results suggest decreased allocation of attention to
aversive social signals, and increased adherence to positive
social signals after oxytocin treatment in patients with
chronic depression. Given the psychopathological differ-
ences between episodic and chronic depression, the present
study might be considered a point of departure for deeper
research into the role of oxytocin in chronic depression – a
disorder characterized by pronounced and disabling diffi-
culties in social cognition and functioning [1].
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